- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01983501
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine; T-DM1)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1b, open-label study of tucatinib (ONT-380) given in combination with ado-trastuzumab emtansine (T-DM1) to patients with HER2+ breast cancer.
This study will use a 3+3 dose escalation design to evaluate up to four dose levels of tucatinib ONT-380 in order to identify the maximal tolerated dose/recommended dose (MTD/RD) of tucatinib (ONT-380) in combination with T-DM1. T-DM1 will be administered intravenously on day 1 of each cycle (except cycle 1, when it will be administered on day 2 to allow for PK assessments of tucatinib (ONT-380) alone).Tucatinib (ONT-380) will be administered orally, twice per day on days 1-21 of each cycle.
There will be 3-6 evaluable patients enrolled in each cohort in the dose escalation phase, unless that dose is found to be intolerable prior to completion of enrollment. At least 6 evaluable patients are to be treated at a dose level in order for an MTD/RD to be declared. Once an MTD/RD is declared, an additional 24 evaluable patients will be in enrolled in a MTD/RD expansion cohort for a total of 30 evaluable patients to be treated at the MTD/RD.
In addition to the MTD/RD expansion cohort, an optional additional cohort of up to 15 evaluable patients with either untreated, asymptomatic CNS metastases not needing immediate local therapy or progressive CNS metastasis following local therapy may also be enrolled and treated at the MTD/RD. Up to 63 evaluable patients may be treated in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M5T 2M9
- Princess Margaret Cancer Centre
-
-
Quebec
-
Laval, Quebec, Canada, H7M 3L9
- Hospital de la Cite-de-la-Sante
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Washington
-
Tacoma, Washington, United States, 98045
- Northwest Medical Specialties
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HER2+ metastatic breast cancer, documented as HER2+ by FISH and/or 3+ staining by immunohistochemistry.
- History of prior therapy with trastuzumab and a taxane, separately or in combination. For patients in dose escalation and MTD expansion cohorts, prior therapy with trastuzumab and a taxane must have been for metastatic disease. For patients in CNS disease expansion cohorts, trastuzumab and taxane (together or separately) may have been given at any time prior to study enrollment as part of neoadjuvant therapy, adjuvant therapy, or therapy for metastatic disease.
- If female and of child-bearing potential, has negative pregnancy test within 14 days prior to treatment.
- If a sexually active male or a sexually active female of child-bearing potential, agrees to use dual (two concurrent) forms of medically accepted contraception from the time of consent until 6 months after the last dose of either tucatinib (ONT-380) or T-DM1, whichever is longer.
- Signed an informed consent document that has been approved by an institutional review board or independent ethics committee (IRB/IEC).
- Must have target or non-target lesions as per RECIST 1.1.
- All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1, with the following exceptions: alopecia; neuropathy, which must have to resolved to ≤ Grade 2; and congestive heart failure (CHF), which must have been ≤ Grade 1 in severity and must have resolved completely.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
- In the opinion of the Investigator, life expectancy > 6 months.
Adequate hematologic function as defined by:
- Hemoglobin ≥ 9 g/dL
- Absolute neutrophil count (ANC) ≥ 1000 cells/µL
- Platelets ≥ 100,000/µL
Adequate hepatic function as defined by the following:
- Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
- Transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) ≤ 1.5 X ULN (< 2.5 X ULN if liver metastases are present)
- INR and aPTT < 1.5 X ULN unless on medication known to alter INR and aPTT.
- Calculated creatinine clearance ≥ 60 mL/min.
- Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study drug.
Exclusion Criteria:
- Medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
- Patient is breastfeeding.
- Patient was treated with any experimental agent within 14 days or five half-lives of study treatment, whichever is greater.
- Patient was treated with trastuzumab or other antibody based therapy within three weeks of starting study treatment or with chemotherapy or hormonal cancer therapy within two weeks of starting study treatment.
- Patient had prior exposure to a cumulative dose of doxorubicin that exceeded 360 mg/m2 or its equivalent.
- Previous treatment with T-DM1 at any time; or previous treatment with any small molecule HER2 inhibitors including (but not limited to) lapatinib, neratinib, or afatinib within the last 4 weeks prior to initiation of study therapy.
CNS disease:
- Patients with leptomeningeal disease are excluded
- Dose escalation and MTD/RP2D expansion cohort: Patients with symptomatic CNS metastases are excluded. Patients with treated CNS metastases or untreated asymptomatic CNS metastases not requiring immediate local therapy may be eligible. Enrollment of patients with metastases must be approved by the study medical monitor.
- Optional CNS disease expansion cohort: Patients with asymptomatic untreated CNS metastases not needing immediate local therapy or patients with progressive CNS disease following local therapy may be eligible with medical monitor approval.
- History of allergic reactions to compounds of similar chemical or biological composition to T-DM1 or tucatinib (ONT-380), except for a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab which has been successfully managed.
- Patients with uncorrectable electrolyte abnormalities.
- Known to be HIV positive. HIV testing is not required for those patients who are not known to be positive.
- Known carrier of Hepatitis B and / or Hepatitis C (whether active disease or not).
- Known liver disease, autoimmune hepatitis, or sclerosing cholangitis.
- Inability to swallow pills or any significant gastrointestinal diseases, which would preclude adequate absorption of oral medications.
- Use of a strong CYP3A4 inhibitor within three elimination half-lives of the inhibitor prior to the start of study treatment.
- Use of a strong CYP2C8 inducer or inhibitor within three elimination half-lives of the inducer or inhibitor prior to the start of study treatment.
- Radiotherapy within 14 days of study treatment; patient must have recovered from acute effects of radiotherapy to baseline.
- Known impaired cardiac function or clinically significant cardiac disease such as ventricular arrhythmia requiring therapy, congestive heart failure and uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).
- Myocardial infarction or unstable angina within 6 months prior to the first dose of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tucatinib (ONT-380) in combination with T-DM1
|
Given twice per day, orally
Given intravenously once every 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response
Time Frame: 12 months
|
12 months
|
|
Incidence of clinical lab abnormalities
Time Frame: 12 months
|
12 months
|
|
Frequency of dose reductions in tucatinib
Time Frame: 12 months
|
12 months
|
|
Frequency of dose reductions in T-DM1
Time Frame: 12 months
|
12 months
|
|
Objective response rate (ORR)
Time Frame: 12 months
|
12 months
|
|
Disease control rate (DCR)
Time Frame: 12 months
|
Defined as best response of complete response (CR), partial response (PR), or stable disease (SD)
|
12 months
|
Clinical benefit rate (CBR)
Time Frame: 12 months
|
Defined as SD for ≥6 months, PR, or CR
|
12 months
|
Progression-free survival (PFS)
Time Frame: Up to approximately 6 years
|
Up to approximately 6 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONT-380-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2 Positive Breast Cancers
-
Molecular Templates, Inc.TerminatedHER2-positive Solid CancersUnited States, Australia, New Zealand
-
Seagen Inc.CompletedHER2 Positive Metastatic Breast CancersUnited States
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Jazz PharmaceuticalsALX Oncology Inc.RecruitingHER2-expressing CancersUnited States
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
Clinical Trials on Tucatinib (ONT-380)
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Seagen Inc.National Cancer Institute (NCI); Academic and Community Cancer Research UnitedCompletedMetastatic Colorectal AdenocarcinomaUnited States, Spain, Belgium, France, Italy
-
Seagen Inc.CompletedHER2 Positive Breast CancerUnited States, Spain, Belgium, Germany, Israel, France, United Kingdom, Austria, Denmark, Italy, Australia, Canada, Czechia, Portugal, Switzerland
-
Seagen Inc.Active, not recruitingHER2 Positive Breast CancerUnited States
-
Seagen Inc.RemeGen Co., Ltd.RecruitingStomach Neoplasms | Breast Neoplasms | Triple Negative Breast Neoplasms | Gastroesophageal Junction Adenocarcinoma | HER2 Positive Breast Neoplasms | HER2 Low Breast NeoplasmsUnited States
-
Seagen Inc.Active, not recruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
-
Seagen Inc.CompletedHER2 Positive Metastatic Breast CancersUnited States
-
University of Alabama at BirminghamJohns Hopkins University; Georgetown University; University of Chicago; University... and other collaboratorsActive, not recruitingMetastatic Breast Cancer | Leptomeningeal DiseaseUnited States
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Seagen Inc.Active, not recruitingUrologic Neoplasms | Uterine Cervical Neoplasms | Uterine Neoplasms | Carcinoma, Non-Small-Cell Lung | Biliary Tract Neoplasms | HER2 Mutations Breast NeoplasmsUnited States, United Kingdom, Spain, Korea, Republic of, Italy, Belgium, Germany, Japan, Netherlands, Poland